Emergency department visits due to new psychoactive substances and other illicit drugs in Taiwan: preliminary results of the Taiwan Emergency Department Drug Abuse Surveillance (TEDAS) project

References

• UNODC. What are NPS? 2020. [cited 2021/8/2]. Available from: https://www.unodc.org/LSS/Page/NPS
   Google Scholar
• EMCDDA U. June 2019 – EMCDDA. European Drug Report describes a complex NPS market. [cited 2020 22 June]. Available from: https://www.unodc.org/LSS/Announcement/Details/af9c6b26-5715-4043-86e6-f6d7a2acad50
   Google Scholar
• Helander A, Backberg M, Hulten P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014;243:23–29.
   PubMed Web of Science ®Google Scholar
• Brandehoff N, Adams A, McDaniel K, et al. Synthetic cannabinoid “black mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN cohort. Clin Toxicol (Phila). 2018;56(3):193–198.
   PubMed Web of Science ®Google Scholar
• Begeman A, Franssen EJF. Lack of detection of new Amphetamine-Like drugs using conventional urinary immunoassays. Ther Drug Monit. 2018;40(1):135–139.
   PubMed Web of Science ®Google Scholar
• Pettersson Bergstrand M, Helander A, Hansson T, et al. Detectability of designer benzodiazepines in CEDIA, EMIT II plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal. 2017;9(4):640–645.
   PubMed Web of Science ®Google Scholar
• Regester LE, Chmiel JD, Holler JM, et al. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits. J Anal Toxicol. 2015;39(2):144–151.
   PubMed Web of Science ®Google Scholar
• Logan BK, Mohr ALA, Friscia M, et al. Reports of adverse events associated with use of novel psychoactive substances, 2013–2016: a review. J Anal Toxicol. 2017;141(7):573–610.
   PubMed Web of Science ®Google Scholar
• Kraemer M, Boehmer A, Madea B, et al. Death cases involving certain new psychoactive substances: a review of the literature. Forensic Sci Int. 2019;298:186–267.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Guerrieri D, Vikingsson S, et al. Fatal poisonings associated with new psychoactive substances. Handb Exp Pharmacol. 2018;252:495–541.
   PubMedGoogle Scholar
• Wood DM, Heyerdahl F, Yates CB, et al. The european drug emergencies network (Euro-DEN). Clin Toxicol (Phila). 2014;52(4):239–241.
   PubMed Web of Science ®Google Scholar
• Monte AA, Hopkinson A, Saben J, et al. The psychoactive surveillance consortium and analysis network (PSCAN): the first year. Addiction. 2020;115(2):270–278.
   PubMed Web of Science ®Google Scholar
• Vallersnes OM, Persett PS, Oiestad EL, et al. Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway. Clin Toxicol (Phila). 2017;55(7):636–644.
   PubMed Web of Science ®Google Scholar
• Feng LY, Li JH. New psychoactive substances in Taiwan: challenges and strategies. Curr Opin Psychiatry. 2020;33(4):306–311.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Wu SC, Tsay WI, et al. Differences in prevalence, socio-behavioral correlates, and psychosocial distress between club drug and hard drug use in Taiwan: results from the 2014 national survey of substance use. Int J Drug Policy. 2017;48:99–107.
   PubMed Web of Science ®Google Scholar
• Weng TI, Chen LY, Chen JY, et al. Characteristics of analytically confirmed illicit substance-using patients in the emergency department. J Formos Med Assoc. 2020;119(12):1827–1834.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Su MK, Hoffman RS. Characteristics of novel psychoactive substance exposures reported to New York city poison center, 2011–2014. Am J Drug Alcohol Abuse. 2016;42(1):39–47.
   PubMed Web of Science ®Google Scholar
• Webb NE, Wood DM, Greene SL, et al. Change in the new psychoactive substances associated with emergency department acute toxicity presentations associated with the introduction of the UK 2016 psychoactive substances act. Clin Toxicol (Phila). 2019;57(1):36–41.
   PubMed Web of Science ®Google Scholar
• Euro-DEN. Final report of the European drug emergencies network (Euro-DEN) March 2015 [cited 2021 June 10]. Available from: https://www.emcdda.europa.eu/system/files/attachments/12440/Euro_DEN-final-report-2015.pdf
   Google Scholar
• Weinstein AM, Rosca P, Fattore L, et al. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 2017;8:156–156.
   PubMed Web of Science ®Google Scholar
• Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, et al. Khat and synthetic cathinones: a review. Arch Toxicol. 2014;188(1):15–45.
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Leyrer-Jackson JM, Oliver CF, et al. DARK classics in chemical neuroscience: cathinone-derived psychostimulants. ACS Chem Neurosci. 2018;9(10):2379–2394.
   PubMed Web of Science ®Google Scholar
• Schifano F, Napoletano F, Arillotta D, et al. The clinical challenges of synthetic cathinones. Br J Clin Pharmacol. 2020;86(3):410–419.
   PubMed Web of Science ®Google Scholar
• Lee J, Yang S, Kang Y, et al. Prevalence of new psychoactive substances in northeast asia from 2007 to 2015. Forensic Sci Int. 2017;272:1–9.
   PubMed Web of Science ®Google Scholar
• Cheng WC, Dao KL. Prevalence of drugs of abuse found in testing of illicit drug seizures and urinalysis of selected population in Hong Kong. Forensic Sci Int. 2019;299:6–16.
   PubMed Web of Science ®Google Scholar
• Chen HY, Chien WC, Huang MN, et al. Analytically confirmed eutylone (bk-EBDB) exposure in emergency department patients. Clin Toxicol (Phila). 2021;59(9):846–848.
   Web of Science ®Google Scholar
• Ling DA, Weng TI, Chen JY, et al. Clinical manifestation and quantitative urinary analysis of N-ethylnorpentylone abuse in patients to the emergency department. Clin Toxicol (Phila). 2020;58(9):935–937.
   PubMed Web of Science ®Google Scholar
• Weng TI, Su PI, Chen JY, et al. Analytically confirmed 4-Methyl-N-ethylnorpentedrone (4-MEAP), a synthetic cathinone, in cases presenting to an emergency department. Clin Toxicol (Phila). 2020;58(1):65–66.
   PubMed Web of Science ®Google Scholar
• Weng TI, Chin LW, Chen LY, et al. Clinical characteristics of patients admitted to emergency department for the use of ketamine analogues with or without other new psychoactive substances. Clin Toxicol (Phila). 2021;59(6):528–531.
   PubMed Web of Science ®Google Scholar
• Chawarski MC, Hawk K, Edelman EJ, et al. Use of Amphetamine-Type stimulants among emergency department patients with untreated opioid use disorder. Ann Emerg Med. 2020;76(6):782–787.
   PubMed Web of Science ®Google Scholar
• Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;93:14–20.
   Google Scholar
• Fattore L, Marti M, Mostallino R, et al. Sex and gender differences in the effects of novel psychoactive substances. Brain Sci. 2020;10(9):606.
   Web of Science ®Google Scholar
• Daniel JJ, Hughes RN. Increased anxiety and impaired spatial memory in young adult rats following adolescent exposure to methylone. Pharmacol Biochem Behav. 2016;146–147:44–49.
   PubMed Web of Science ®Google Scholar
• Alsufyani HA, Docherty JR. Gender differences in the effects of cathinone and the interaction with caffeine on temperature and locomotor activity in the rat. Eur J Pharmacol. 2017;809:203–208.
   PubMed Web of Science ®Google Scholar